Aytu BioPharma Balance Sheet

Financials in millions USD. Fiscal year is July - June.

Millions USD. Fiscal year is Jul - Jun.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Jun '25 Jun 30, 2025	Jun '24 Jun 30, 2024	Jun '23 Jun 30, 2023	Jun '22 Jun 30, 2022	Jun '21 Jun 30, 2021
Cash & Equivalents	30.03	30.95	20.01	22.99	19.36	49.65
Cash & Short-Term Investments	30.03	30.95	20.01	22.99	19.36	49.65
Cash Growth	47.20%	54.71%	-12.96%	18.72%	-61.01%	3.26%
Receivables	30.92	31.16	23.53	28.73	21.71	28.18
Inventory	8.66	11.43	12.14	8.51	10.85	16.34
Prepaid Expenses	6.64	5.64	5.1	5.43	7.38	9.78
Restricted Cash	-	-	-	-	-	0.25
Other Current Assets	-	-	1.12	5.43	0.63	1.04
Total Current Assets	76.24	79.18	61.89	71.08	59.93	105.23
Property, Plant & Equipment	1.44	1.59	1.52	3.61	6.3	8.7
Goodwill	-	-	-	-	-	65.8
Other Intangible Assets	43.58	42.2	52.45	57.44	70.63	85.46
Long-Term Deferred Tax Assets	-	0.25	0.76	1.38	-	-
Other Long-Term Assets	0.74	0.95	1.47	2.96	0.77	0.47
Total Assets	122	124.18	118.1	136.46	137.62	265.67
Accounts Payable	14.26	10.6	10.31	12.55	10.99	19.26
Accrued Expenses	40.16	15.26	22.26	24.54	25.71	30.72
Short-Term Debt	9.08	9.06	2.4	1.56	3.81	7.93
Current Portion of Long-Term Debt	1.86	1.86	1.86	-	-	16.57
Current Portion of Leases	-	0.14	0.71	1.34	0.1	0.1
Other Current Liabilities	0.22	26.15	24.69	29.02	23.84	34.86
Total Current Liabilities	65.56	63.06	62.23	69.02	64.44	109.44
Long-Term Debt	10	10.9	10.88	14.71	14.2	-
Long-Term Leases	-	0.99	0.58	0.83	0.08	0.18
Long-Term Deferred Tax Liabilities	-	0.25	0.76	1.38	-	-
Other Long-Term Liabilities	32.24	30.02	15.94	11.17	14.59	18.48
Total Liabilities	107.8	105.21	90.38	97.11	93.32	128.1
Common Stock	0	0	0	0	-	0
Additional Paid-In Capital	356.35	352.5	347.69	343.49	331.39	315.86
Retained Earnings	-342.15	-333.54	-319.97	-304.13	-287.08	-178.3
Total Common Equity	14.2	18.97	27.72	39.36	44.31	137.57
Shareholders' Equity	14.2	18.97	27.72	39.36	44.31	137.57
Total Liabilities & Equity	122	124.18	118.1	136.46	137.62	265.67
Total Debt	20.93	22.94	16.42	18.45	18.19	24.78
Net Cash (Debt)	9.1	8.02	3.59	4.53	1.17	24.87
Net Cash Growth	179.16%	123.38%	-20.87%	286.86%	-95.29%	-46.03%
Net Cash Per Share	1.12	1.28	0.65	1.36	0.80	29.70
Filing Date Shares Outstanding	10.73	9.91	6.17	5.53	3.12	1.38
Total Common Shares Outstanding	10.73	8.98	5.97	5.52	1.93	1.37
Working Capital	10.68	16.12	-0.34	2.06	-4.51	-4.2
Book Value Per Share	1.32	2.11	4.64	7.13	22.97	100.08
Tangible Book Value	-29.38	-23.24	-24.74	-18.08	-26.32	-13.7
Tangible Book Value Per Share	-2.74	-2.59	-4.14	-3.28	-13.65	-9.97
Machinery	-	1.08	2.78	4.29	4.45	5
Construction In Progress	-	-	-	0.11	-	0.2
Leasehold Improvements	-	0.16	0.04	1	1	0.96

Source: S&P Global Market Intelligence. Standard template. Financial Sources.